Amarin Corp ADR(AMRN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.3 | Insider Own | 0.02% | Shs Outstand | 21.1M | Perf Week | 4.09% |
| Market Cap | 0.25B | Forward P/E | - | EPS next Y | 42.55% | Insider Trans | - | Shs Float | 21.1M | Perf Month | -9.81% |
| Enterprise Value | -0.06B | PEG | - | EPS next Q | -0.1 | Inst Own | 20.09% | Short Float | 2.52% | Perf Quarter | -15.61% |
| Income | -0.03B | P/S | 1.36 | EPS this Y | -565.48% | Inst Trans | 0.1% | Short Ratio | 8.02 | Perf Half Y | -14.4% |
| Sales | 0.19B | P/B | 0.57 | EPS next 5Y | - | ROA | -4.18% | Short Interest | 0.53M | Perf YTD | -14.37% |
| Book/sh | 21.12 | P/C | 0.8 | EPS past 3/5Y | 29.16% -14.55% | ROE | -5.96% | 52W High | -41.91% ($20.57) | Perf Year | -37.89% |
| Cash/sh | 14.91 | P/FCF | 16.23 | Sales past 3/5Y | -16.59% -19.12% | ROIC | -6.03% | 52W Low | 6.22% ($11.25) | Perf 3Y | -13.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 74.2% | Gross Margin | 40.42% | Volatility(W/M) | 3.53% 3.08% | Perf 5Y | -86.95% |
| Dividend TTM | - | EV/Sales | -0.31 | Sales Y/Y TTM | -15.63% | Oper. Margin | -12.88% | ATR (14) | 0.37 | Perf 10Y | -82.48% |
| Dividend Ex-Date | - | Quick Ratio | 2.67 | EPS Q/Q | 46.7% | Profit Margin | -14.57% | RSI (14) | 42.59 | Recom | 5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.67 | Sales Q/Q | -42.58% | SMA20 | 0.49% ($11.89) | Beta | 0.81 | Target Price | $12.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/10/28 | SMA50 | -8.55% ($13.07) | Rel Volume | 0.86 | Prev Close | $12.09 |
| Employees | 80 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -100% -5.25% | SMA200 | -16.75% ($14.35) | Avg Volume(3M) | 0.07M | Price | $11.95 |
| IPO | 1993/4/1 | Option/Short | Yes/Yes | Trades | 687 | Volume | 56,894 | Change | -1.16% |
Amarin is a pharmaceutical company focused on reducing the risk of cardiovascular disease. Its flagship product is Vascepa (generic name: icosapent ethyl), a prescription drug based on a purified omega-3 fatty acid (EPA), and the company operates in the area of cardiovascular risk management for patients with high triglyceride levels. It is a small pharmaceutical company pursuing expansion in the U.S. and global markets.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded about as much as usual. That is 86% of its average volume.
Next earnings report: October 28
1 days to go.
AMRN has a sound balance sheet but weak earning power
Of every $100 in sales, $12.88 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -565.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $136. Peers typically go for $327.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Sell.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #17 of 21 in the industry
Based on market cap of $252M.
OGN#15 Organon & Co $4B PER 17.6 
GRFS#16 Grifols SA ADR $2B PER 10.4 AMRN#17 Amarin Corp ADR $252M PER - 
NSRX#18 Nasus Pharma Ltd $39M PER - 
MIRA#19 Mira Pharmaceuticals Inc $23M PER - 
FAQ
What kind of company is AMRN?
AMRN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of AMRN?
The market cap of AMRN is approximately $252M, ranking 3,820 within its sector.
What is the 52-week high and low for AMRN?
AMRN has recorded a 52-week high of $20.57 and a low of $11.25.
